{"url_path":"/sec/odtx/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1882782/0001193125-26-274290-index.html","accession_number":"0001193125-26-274290","cik":"0001882782","ticker":"ODTX","issuer_name":"Odyssey Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1882782/0001193125-26-274290-index.html","primary_entity_key":"0001882782","primary_entity_name":"Odyssey Therapeutics, Inc."},"word_count":79,"has_tables":true,"body_markdown":"Item 1. Legal Proceedings.\n\nFrom time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors."}